About BioImagene
BioImagene is a Healthcare company based in Sunnyvale (United States) founded in 2003, and was acquired by Roche in August 2010. Digital pathology tools are developed for diagnostics and drug discovery. BioImagene has raised $40.2 million across 5 funding rounds from investors including Roche, Burrill and Company and Next47. The company has 40 employees. BioImagene has completed 1 acquisition, including Tissue Informatic. Its focus areas include Life Sciences, Oncology, In-Vitro Diagnostic Tests and Diversified. Its legal entity is BioImagene Inc. Its competitors include Guardant Health, Natera and Foundation Medicine; 3 of its 3 listed competitors have raised funding.
Company details
BioImagene was founded in 2003 and is based in Sunnyvale, United States, within the digital pathology sector. IHC algorithms are provided for cancers including breast (HER2, ERPR, p53, Ki67), brain and prostate (Ki67), multiple myeloma (CD138), and lymphoma (CD3CD20). The iSlide input device is offered for microscope-based manipulation of digital slide images, while iScan Coreo Au scanners support applications such as image analysis, telepathology, remote microscopy, and education.
- Headquarters Sunnyvale, United States
- Employees 40
- Stage Acquired
- SectorsHealthcare
- Website bioimagene.com
- Social LinkedIn
- Acquired by Roche (Aug 2010)
- Legal Name Bioimagene Inc
Funding Insights of BioImagene
BioImagene has successfully raised a total of $40.2M across 5 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $40.2M
- Total Rounds 5
- First Round $10M
(Jun 2003)
- Investors Count 9
All 5 funding rounds of BioImagene with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct 2008 | Series D | – | – | ||
| Apr 2008 | $26M | Series D | – | – | |
| Oct 2004 | $4.2M | Series B | – | – | |
| Jun 2003 | $10M | Series C | – | – | |
| Jun 2003 | Seed | – | – |
10 investors in total: 10 institutional.
Investors in BioImagene
BioImagene has secured backing from 10 investors, including venture fund and institutional investors. Prominent investors backing the company include Roche, Burrill and Company and Next47.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture investments in systems, infrastructure, and applications for enterprise founders. | next47.com | |||
Strategic investments in healthcare technologies and data innovations. | ascensionventures.org | |||
Venture capital firm investing in technology and healthcare sectors. | 2000 | artiman.com | ||
Tech companies are funded by corporate-backed venture capital firm. | iccpventurepartners.com | Makati, Philippines | ||
| authosis.com | ||||
| tuputeleventures.com | ||||
C2C Ventures is engaged in seed-stage venture capital investment for university entrepreneurs. | 1999 | c2cventures.com | Stanford, United States | |
Multi-category products are listed on an online B2B platform. | 1994 | burrillandco.com | Wuxi, China | |
Delivers comprehensive managed housekeeping services for healthcare facilities. | 2002 | nationalhs.com | Richmond, United States | |
Pharmaceuticals and diagnostics kits are developed for various diseases. | 1896 | roche.com | Basel, Switzerland |
Investor details for BioImagene
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of BioImagene
442 people are tracked at BioImagene (182 in leadership, 10 in board & advisors, 250 in team); the tracked headcount is 40.
| Name | Role | Group |
|---|---|---|
Yasmin Köller | Head Of Integrated Marketing | Leadership |
Dheeraj Manchanda | Head - Operations & Channel Management | Leadership |
Joab C. | Director, Global Diagnostics Partnering | Leadership |
Lubomira Osten | Finance Business Partner - Diabetes Care R&d | Leadership |
Matthias Ochs | Head Managed Service Center | Leadership |
Nims Dhawan | Global OD Consulting Partner | Leadership |
Mallorie Poiseau | Executive Recruiting Partner EMEA / APAC | Leadership |
Yunus Rasmi | Head Of Operation Single Use Technology | Leadership |
Elie Fux | Group Head Mass Spectrometry Applications | Leadership |
Hafsa Shamsie | Managing Director | Leadership |
Roel Panneels | Head Of Business Operations | Leadership |
Veena Gonsalves | Head Channel Partner Management | Leadership |
Nitin Wadhwa | Director Sales | Leadership |
Xuemin Liu | Director, Companion Diagnostics, Roche Diagnostics | Leadership |
Christoph Rutz | Chapter Lead R&d | Department Head, R&d Corelab | Leadership |
Heather Yoder | Director, People & Culture | Leadership |
Taksina Ratanasakdi | Chief Transformation Officer (agile Transformation) & Enterprise Finance | Leadership |
Matheus B Vieira | President & General Manager - Roche Diagnostics Canada | Leadership |
Rahul Kamath | Chief Operating Officer | Leadership |
Chinmay Trivedi | Head Of Informatics | Cluster Lead, Australia And New Zealand | Roche Pharma/ Diagnostics | Leadership |
422 more people are available in the full profile.
Complete people profiles for BioImagene
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Investments & Acquisitions by BioImagene
BioImagene has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Tissue Informatic.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Tissue imaging systems are developed for biotechnology quantitative analysis. | tissueinformatics.com | Pittsburgh, United States | 1998 | Jun 2006 | •••• |
Complete acquisition details for BioImagene
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of BioImagene
5 dated milestones of BioImagene across 7 years, from founding to its latest funding, stage changes and deals.
- Founded BioImagene is founded.
- Funding First funding round of $10.0M.
- Acquisition Acquires Tissue Informatic.
- Funding Latest funding round, Series D,.
- Exit Acquired by Roche.
Competitors of BioImagene
BioImagene has 3 listed competitors in our database, 3 of them funded. They include Guardant Health, Natera and Foundation Medicine.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| guardanthealth.com | 2012 | Redwood, United States | $557.5M | 1,351 | Digital sequencing technology for cancer detection is developed. | |
| natera.com | 2004 | Redwood, United States | $152.1M | 3,293 | Developer of cell-free DNA testing for oncology, women’s health, and organ health | |
| foundationmedicine.com | 2010 | Cambridge, United States | $96.5M | 1,707 | Genomics-based diagnostic tests for cancer are provided. |
Detailed competitors of BioImagene
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Oncology
3 companies that operate in the same segment as BioImagene (Oncology) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Bioimagene
Complete news archive for BioImagene
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about BioImagene
BioImagene was founded in 2003.
BioImagene is headquartered in Sunnyvale, United States. It is registered at Sunnyvale, California, United States.
BioImagene is a funded company, having raised a total of $40.2M across 5 funding rounds to date. The company's 1st funding round was a Series C of $10M, raised on Jun 2003.
BioImagene has 40 employees.
BioImagene was founded in 2003 and is based in Sunnyvale, United States, within the digital pathology sector. IHC algorithms are provided for cancers including breast (HER2, ERPR, p53, Ki67), brain and prostate (Ki67), multiple myeloma (CD138), and lymphoma (CD3CD20). The iSlide input device is offered for microscope-based manipulation of digital slide images, while iScan Coreo Au scanners support applications such as image analysis, telepathology, remote microscopy, and education.
BioImagene's top competitors include Guardant Health, Foundation Medicine and Natera.
BioImagene has made 1 acquisition, including Tissue Informatic.
BioImagene has 10 investors. Key investors include Roche, Burrill and Company, Next47, Ascension Ventures, and National Healthcare Services.
BioImagene operates through Bioimagene Inc.
Yes. BioImagene was acquired by Roche in August 2010.